A Phase 2 interventional study of ATH434 in Multiple System Atrophy, sponsored by Alterity Therapeutics. Completed at 1 site in United States. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Alterity Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Multiple System Atrophy with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Multiple System Atrophy · United States.
Among the 90 studies in Multiple System Atrophy with a site in United States, this one is the 47th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2023, is one of 17 in phase 2, and was the 72nd registered.
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
Browse Multiple System Atrophy studies →21 of the 90 studies in Multiple System Atrophy with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
MODAG GmbH · Sites in United States
Ages 18–60 · Healthy volunteers
MODAG GmbH · Sites in United States
Ages 50–80 · Healthy volunteers
Teva Branded Pharmaceutical Products R&D LLC · Sites in United States, France, Germany and 4 more countries
Ages 30+
Tiziana Life Sciences LTD · Sites in United States
Ages 30–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 20 · Phase 3 7 · Phase 4 2
First in 1995; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 41 across 134 interventional studies indexed under Multiple System Atrophy.
Median enrollment 35 across the 57 interventional studies, 184 across the 31 observational. Of the 53 that completed or were terminated, 19 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 90 have an industry lead sponsor. The 10 most frequent:
Alterity Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Alterity Therapeutics has 4 studies filed under Multiple System Atrophy — fewer than ten, so there is no comparison to draw.
19 of the studies in Multiple System Atrophy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT03042988Vanderbilt University Medical CenterOvernight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension | 2026-11-30 |
| NCT05167721Mayo ClinicRandomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy | 2026-12 |
| NCT02726711Vanderbilt UniversityReduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic | 2026-12 |
| NCT03312556Vanderbilt University Medical CenterTreatment of Supine Hypertension in Autonomic Failure (CPAP) | 2026-12-21 |
Add all 19 to your calendar (.ics) → With an account.
Among the 90 studies in Multiple System Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ATH434
ATH434 taken by mouth two times per day
Change in brain volume as measured by MRI
Time frame: Change from Baseline to Week 52
Change in iron content in substantia nigra as measured by MRI
Time frame: Change from Baseline to Week 52
Change in Unified MSA Rating Scale (UMSARS) Score
Time frame: Change from Baseline to Week 52
Change in Patient Global Impression of Change (PGI-C)
Time frame: Change from Baseline to Week 52
Change in Clinical Global Impression of Change (CGI-C)
Time frame: Change from Baseline to Week 52
Change in Neurofilament Light Chain Levels
Time frame: Change from Baseline to Week 52
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Feb 2025, 21 months.
Of 19 phase 2 interventional studies under Multiple System Atrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 32. This study's 21 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ATH434
Alterity Therapeutics